- Home
- NKTX vs MIST Comparison
NKTX vs MIST Comparison
Compare NKTX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- MIST
- Stock Information
- Founded
- NKTX 2015
- MIST 2003
- Country
- NKTX United States
- MIST Canada
- Employees
- NKTX N/A
- MIST N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- NKTX Health Care
- MIST Health Care
- Exchange
- NKTX Nasdaq
- MIST Nasdaq
- Market Cap
- NKTX 123.5M
- MIST 145.3M
- IPO Year
- NKTX 2020
- MIST N/A
- Fundamental
- Price
- NKTX $1.97
- MIST $1.96
- Analyst Decision
- NKTX Strong Buy
- MIST Strong Buy
- Analyst Count
- NKTX 5
- MIST 3
- Target Price
- NKTX $13.50
- MIST $6.33
- AVG Volume (30 Days)
- NKTX 539.6K
- MIST 1.2M
- Earning Date
- NKTX 11-06-2025
- MIST 11-11-2025
- Dividend Yield
- NKTX N/A
- MIST N/A
- EPS Growth
- NKTX N/A
- MIST N/A
- EPS
- NKTX N/A
- MIST N/A
- Revenue
- NKTX N/A
- MIST N/A
- Revenue This Year
- NKTX N/A
- MIST N/A
- Revenue Next Year
- NKTX N/A
- MIST N/A
- P/E Ratio
- NKTX N/A
- MIST N/A
- Revenue Growth
- NKTX N/A
- MIST N/A
- 52 Week Low
- NKTX $1.31
- MIST $0.63
- 52 Week High
- NKTX $6.49
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- NKTX 41.11
- MIST 66.84
- Support Level
- NKTX $2.00
- MIST $1.75
- Resistance Level
- NKTX $2.08
- MIST $1.83
- Average True Range (ATR)
- NKTX 0.11
- MIST 0.09
- MACD
- NKTX -0.03
- MIST 0.01
- Stochastic Oscillator
- NKTX 2.35
- MIST 90.91
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).